Number of patients necessary to treat (NNT) and number of prevented fractures (NPF): Clinical efficiency of osteoporosis therapy with alendronate diphosphonate;Numero de pacientes que es necesario tratar y numero de fracturas prevenidas: Eficiencia clinica del tratamiento de la osteoporosis con el difosfonato alendronato

Revista Clinica Espanola

Volumn 199, Issue 6, 1999, Pages 349-355

  Riancho, J A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Fractures; Osteoporosis; Prevention; Therapy

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; DRUG EFFICACY; FEMALE; FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MODEL; OSTEOPOROSIS; VERTEBRA FRACTURE; WRIST FRACTURE; AGE; COMPARATIVE STUDY; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; RISK FACTOR; SPINE FRACTURE; STATISTICAL ANALYSIS; WRIST INJURY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; DATA INTERPRETATION, STATISTICAL; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; SPINAL FRACTURES; WRIST INJURIES;

EID: 0033144499     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Seeman E. Osteoporosis: trials and tribulations. Am J Med 1997; 103 (suppl 2A):74S-89S.
2. McQuay HJ, Moore RA. Using numerical results from systematic reviews. Ann Intern Med 1997; 126:712-720.
3. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995; 310:452-454.
4. Chatellier G, Zapletal E, Lemaitre D, Menaard J, Degoulet P. The number needed to treat: a clinically useful nomogram in its proper context. Br Med J 1996; 312:426-429.
5. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporosis Int 1996; 6:265-275.
6. Kanis JA. Treatment of osteoporosis in elderly women. Am J Med 1995: 98 (suppl 2A):60S-66S.
7. Seeley DG, Browner WS, Nevitt MC, Genant HK, Dcott JC, Cummings SR. Which fractures are associated with low apendicular bone mass. Ann Intern Med 1991; 115:837-842.
8. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int 1998; 8 (suppl 4): 1-88.
9. Eastell R. Forearm fracture. Bone 1996; 18 (suppl 3):203S-207S.
10. Baron JA, Barrett JA, Karagas R. The epidemiology of peripheral fractures. Bone 1996; 18 (suppl 3):209S-213S.
11. Melton LJ, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989; 129:1.000-1.011.
12. Baudoin C, Fardellone P, Potard V, Sebert JL. Fractures of the proximal femur in Picardy, France, in 1987. Osteoporosis Int 1993; 3:43-49.
13. Lauritzen JB, Schwartz P, Lund B, McNair P, Transbol I. Changing incidence and residual lifetime risk of common osteoporosis-related fractures Osteoporosis Int 1993; 3:127-132.
14. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348:1.535-1.541.
15. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 1997; 277:1.159-1.164.
16. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density an the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333:1.437-1.443.
17. Stock JL, Bell NH, Chesnut III CH, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997; 103:291-297.
18. Windeler J, Lange S. Events per person-year - a dubious concept. Br Med J 1995; 310:454-456.
19. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151:2.026-2.032.
20. Looker AC, Johnston CC, Wahner HW, et al. Prevalence of low femoral density in older US women from NHANES III. J Bone Miner Res 1995; 10:796-802.
21. Díaz Curiel M, Díez Pérez A, Gómez Alonso C, eds. Nuevas fronteras en el estudio de la densidad ósea en la población española. Madrid: FHOEMO, SEIOMM, RPR, 1996.
22. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fracture. Epidemiol Rev 1997; 19:244-257.
23. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo study. JAMA 1997; 277:543-547.
24. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103 (suppl 2A):12S-19S.
25. Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The study of osteoporotic fractures. Arch Intern Med 1996; 156:1.521-1.525.
26. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9:1.137-1.141.
27. Miller PD, Bonnick SL, Rosen CJ. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. Calcif Tissue Int 1996; 58:207-214.
28. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int 1996; 6:256-261.
29. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996; 312:1.254-1.259.
30. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-79.
31. Sackett DL, Richardsson WS, Rosemberg W, Haynes RB. Evidence-based Medicine. Edinburgh: Churchill Livingston, 1997.
32. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332:767-773.
33. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919-923.
34. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1.301-1.307.
35. Sacks FM, Pfeeffer MA, Moye LAA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1.001-1.009.
36. Scandinavian Sinvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinvastatin Survival Study (4S). Lancet 1994; 344:1.383-1.389.